<SEC-DOCUMENT>0001640334-20-002907-index.html : 20201120 <SEC-HEADER>0001640334-20-002907.hdr.sgml : 20201120 <ACCEPTANCE-DATETIME>20201120131350 ACCESSION NUMBER: 0001640334-20-002907 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 7 CONFORMED PERIOD OF REPORT: 20201119 FILED AS OF DATE: 20201120 DATE AS OF CHANGE: 20201120 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NYMOX PHARMACEUTICAL CORP CENTRAL INDEX KEY: 0001018735 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12033 FILM NUMBER: 201331760 BUSINESS ADDRESS: STREET 1: 9900 CAVENDISH BLVD., SUITE 306 STREET 2: ST. LAURENT CITY: QUEBEC CANADA STATE: A8 ZIP: H4M 2V2 BUSINESS PHONE: 1-800-936-9669 MAIL ADDRESS: STREET 1: 9900 CAVENDISH BLVD., SUITE 306 STREET 2: ST. LAURENT CITY: QUEBEC CANADA STATE: A8 ZIP: H4M 2V2 </SEC-HEADER> <DOCUMENT> <TYPE>6-K <SEQUENCE>1 <FILENAME>nymox_6k.htm <DESCRIPTION>FORM 6-K <TEXT> Document 1 - file: nymox_6k.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-99.1 <SEQUENCE>2 <FILENAME>nymox_ex991.htm <DESCRIPTION>EX-99.1 <TEXT> Document 2 - file: nymox_ex991.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-99.2 <SEQUENCE>3 <FILENAME>nymox_ex992.htm <DESCRIPTION>EX-99.2 <TEXT> Document 3 - file: nymox_ex992.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-99.3 <SEQUENCE>4 <FILENAME>nymox_ex993.htm <DESCRIPTION>EX-99.3 <TEXT> Document 4 - file: nymox_ex993.htm
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>5 <FILENAME>nymox_ex992img1.jpg <TEXT> Document 5 - file: nymox_ex992img1.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>6 <FILENAME>nymox_ex993img1.jpg <TEXT> Document 6 - file: nymox_ex993img1.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>7 <FILENAME>nymox_ex993img2.jpg <TEXT> Document 7 - file: nymox_ex993img2.jpg
</DOCUMENT> </SEC-DOCUMENT>